The outcomes of transanal endorectal pull-through for Hirschsprung's disease according to the mucosectomy-commencing points: A study based on the results of a nationwide survey in Japan.


Journal

Journal of pediatric surgery
ISSN: 1531-5037
Titre abrégé: J Pediatr Surg
Pays: United States
ID NLM: 0052631

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 18 08 2019
accepted: 24 08 2019
pubmed: 16 11 2019
medline: 26 3 2020
entrez: 16 11 2019
Statut: ppublish

Résumé

Although the mucosectomy-commencing points on transanal endorectal pull-through (TAEPT) differ among reports, the optimal point is unclear. This study assessed the outcomes among different mucosectomy-commencing points. We conducted a nationwide survey from 2008 to 2012. The data of 1,087 Hirschsprung's disease patients were collected, and data on those who underwent TAEPT were extracted. The patients were divided according to the mucosectomy-commencing points into two groups: in Group A, mucosectomy was started ≥5 mm from the dentate line (DL), and in Group B, mucosectomy was started <5 mm from the DL. The extent of the aganglionic segment and postoperative complications in the month after TAEPT were compared. The data of 327 patients were extracted (Group A, n=155; B, n=172). Aganglionosis extending to the sigmoid colon was the most frequent in both groups. Regarding postoperative complications, the patients of each group experienced enterocolitis (Group A: 8.4%; B: 7.6%) and incontinence (A: 3.9%; B: 2.9%). The incidence of rectal mucosal prolapse was significantly greater in Group B (4.1%); (A: 0%, p=0.02). Although the outcomes of TAEPT were comparable in both groups, rectal mucosal prolapse was significantly frequent in patients in whom the commencing point was <5 mm from the DL. Retrospective study LEVEL OF EVIDENCE: Level III.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Although the mucosectomy-commencing points on transanal endorectal pull-through (TAEPT) differ among reports, the optimal point is unclear. This study assessed the outcomes among different mucosectomy-commencing points.
METHODS METHODS
We conducted a nationwide survey from 2008 to 2012. The data of 1,087 Hirschsprung's disease patients were collected, and data on those who underwent TAEPT were extracted. The patients were divided according to the mucosectomy-commencing points into two groups: in Group A, mucosectomy was started ≥5 mm from the dentate line (DL), and in Group B, mucosectomy was started <5 mm from the DL. The extent of the aganglionic segment and postoperative complications in the month after TAEPT were compared.
RESULTS RESULTS
The data of 327 patients were extracted (Group A, n=155; B, n=172). Aganglionosis extending to the sigmoid colon was the most frequent in both groups. Regarding postoperative complications, the patients of each group experienced enterocolitis (Group A: 8.4%; B: 7.6%) and incontinence (A: 3.9%; B: 2.9%). The incidence of rectal mucosal prolapse was significantly greater in Group B (4.1%); (A: 0%, p=0.02).
CONCLUSIONS CONCLUSIONS
Although the outcomes of TAEPT were comparable in both groups, rectal mucosal prolapse was significantly frequent in patients in whom the commencing point was <5 mm from the DL.
TYPE OF STUDY METHODS
Retrospective study LEVEL OF EVIDENCE: Level III.

Identifiants

pubmed: 31727384
pii: S0022-3468(19)30575-5
doi: 10.1016/j.jpedsurg.2019.08.035
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2546-2549

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Satoshi Obata (S)

The Japanese Study Group for Hirshsprung's disease; Department of Pediatric Surgery, Reproductive and Developmental Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.

Satoshi Ieiri (S)

The Japanese Study Group for Hirshsprung's disease; Department of Pediatric Surgery, Field of Developmental Medicine, Kagoshima University, Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan.

Takashi Akiyama (T)

The Japanese Study Group for Hirshsprung's disease; Department of Pediatric Surgery, Hiroshima City Hiroshima Citizen Hospital, 7-33, Moto-machi, Naka-ku, Hiroshima, 730-8518, Japan.

Naoto Urushihara (N)

The Japanese Study Group for Hirshsprung's disease; Department of Pediatric Surgery, Shizuoka Children's Hospital, 860, Urushiyama, Aoi-ku, Shizuoka, 420-0953, Japan.

Hisayoshi Kawahara (H)

The Japanese Study Group for Hirshsprung's disease; Department of Pediatric Surgery, Hamamatsu University Hospital, 1-20-1, Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan.

Masayuki Kubota (M)

The Japanese Study Group for Hirshsprung's disease; Department of Pediatric Surgery, Niigata University Graduate School of Medicine and Dental Sciences, 1-757, Asahimachi-Dori, Chuo-ku, Niigata, 951-8510, Japan.

Miyuki Kono (M)

The Japanese Study Group for Hirshsprung's disease; Department of Pediatric Surgery, Kanazawa Medical University, 1-1, Daigaku, Uchinada-machi, Kahoku-gun, Ishikawa, 920-0293, Japan.

Yuji Nirasawa (Y)

The Japanese Study Group for Hirshsprung's disease; Department of Pediatric Surgery, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo, 181-0004, Japan.

Shohei Honda (S)

The Japanese Study Group for Hirshsprung's disease; Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, 5, Kita-14jo-nishi, Kita-ku, Sapporo, Hokkaido, 060-8648, Japan.

Masaki Nio (M)

The Japanese Study Group for Hirshsprung's disease; Department of Pediatric Surgery, Tohoku University School of Medicine, 1-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-0872, Japan.

Tomoaki Taguchi (T)

The Japanese Study Group for Hirshsprung's disease; Department of Pediatric Surgery, Reproductive and Developmental Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. Electronic address: taguchi@pedsurg.med.kyushu-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH